Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CASI Pharmaceuticals's revenue for the
three
months ended in Dec. 2025 was €6.17 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €18.18 Mil.
CASI Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2025 was €0.23.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.00.
Warning Sign:
CASI Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of CASI Pharmaceuticals was -39.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -29.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, CASI Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 94.20% per year. The lowest was -83.10% per year. And the median was -21.85% per year.
CASI Pharmaceuticals (FRA:ENM) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CASI Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €18.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (FRA:ENM) has a Revenue of €18.18 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Revenue too high?
CASI Pharmaceuticals' current Revenue is €18.18 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Revenue compare to ITRMF and OGEN?
CASI Pharmaceuticals' Revenue of €18.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Revenue is €18.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Revenue of €18.18 Mil. The stock's GF Value™ is €10.30, compared to a current price of €1.54 — trading 85% below its estimated fair value. The current Revenue is €18.18 Mil. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Revenue is €18.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 85% below its estimated GF Value™ of €10.30.
Key valuation signals for FRA:ENM:
Revenue: €18.18 Mil
GF Value™: €10.30 vs. price of €1.54 (85% below fair value)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
